Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Pyrazinamide (PZA) is a first-line drug for short-course tuberculosis therapy. Resistance to PZA is usually accompanied by loss of pyrazinamidase (PZase) activity in Mycobacterium tuberculosis. PZase converts PZA to bactericidal pyrazinoic acid, and the loss of PZase activity is associated with PZA...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Scorpio, A, Lindholm-Levy, P, Heifets, L, Gilman, R, Siddiqi, S, Cynamon, M, Zhang, Y
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1997
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163747/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9055989/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.41.3.540
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!